Wall Street Sentiment Shifts as Novo Nordisk Faces Mounting Clinical Trial Setbacks
The pharmaceutical landscape recently witnessed a significant recalibration of expectations as market analysts begin questioning the long-term dominance of Novo Nordisk. For
by 
Josh Weiner
Josh Weiner